EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSDORG00000001880
Gene Symbol: KCNK9
3 Cross references
215 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSDORG00000011661
Gene Symbol: KCND3
4 Cross references
261 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSDORG00000000745
Gene Symbol: KCNH2
3 Cross references
253 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSDORG00000011128
Gene Symbol: KCNQ2
3 Cross references
250 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSDORG00000004042
Gene Symbol: KCNQ3
3 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSDORG00000012072
Gene Symbol: KCNQ5
3 Cross references
200 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSDORG00000001780
Gene Symbol: PSEN1
4 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSDORG00000001758
Gene Symbol: PSEN2
4 Cross references
206 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSDORG00000029263
Gene Symbol: PSENEN
3 Cross references
184 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSDORG00000009401
Gene Symbol: PTGDR
4 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSDORG00000006901
Gene Symbol: PTGDR2
3 Cross references
205 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSDORG00000010992
Gene Symbol: PTGER2
4 Cross references
244 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).